Third Harmonic Bio Inc. (THRD)
NASDAQ: THRD
· Real-Time Price · USD
5.15
-0.02 (-0.39%)
At close: May 01, 2025, 3:59 PM
5.16
0.19%
After-hours: May 01, 2025, 04:20 PM EDT
Company Description
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases.
It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Third Harmonic Bio Inc.
| Country | United States |
| IPO Date | Sep 14, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Natalie C. Holles |
Contact Details
Address: 300 Technology Square Cambridge, Massachusetts United States | |
| Website | https://www.thirdharmonicbio.com |
Stock Details
| Ticker Symbol | THRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001923840 |
| CUSIP Number | 88427A107 |
| ISIN Number | US88427A1079 |
| Employer ID | 83-4553503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | Chief Executive Officer & Director |
| Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
| Ommer Chohan | Treasurer & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 16, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 14, 2025 | PRE 14A | Filing |
| Mar 27, 2025 | S-8 | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |